Celldex Therapeutics

At the Cantor conference, Celldex presented Barzolvolimab as its lead candidate for chronic spontaneous urticaria (CSU), highlighting strong Phase‑II results (65% angioedema‑free patients vs. 25% for placebo) and a large Phase‑III program enrolling nearly 2,000 patients. CSU data are expected by the end of 2026; the readout will determine commercial prospects and whether other projects such as CDX‑622 and atopic dermatitis studies will continue. Management emphasized a consistent safety profile in about 700 patients treated so far and the potential for a premium‑pricing strategy based on durable efficacy; no financial figures were disclosed. » Mere på de.investing.com

Celldex Therapeutics’ stock rose to a 52-week high of $40.30, giving it a market capitalization of about $3.16 billion; the share has gained 73% over six months and 86.85% year to date. InvestingPro currently rates the stock as overvalued versus its fair value. At the same time, Celldex has discontinued the Phase II study of barzolvolimab in prurigo nodularis after failing to meet the primary and key secondary endpoints, prompting differing analyst price targets (Canaccord slightly lowered, Guggenheim raised, UBS reiterated). Chief Financial Officer Sam Martin announced he will retire in March 2027. » Mere på de.investing.com

Celldex reported that the phase‑2 trial of barzolvolimab in prurigo nodularis did not meet the primary and key secondary endpoints, sending the stock sharply lower in after‑hours trading. Barzolvolimab markedly reduced mast cells and serum tryptase but showed no significant improvement in itch or skin lesions versus placebo. Celldex is discontinuing the prurigo nodularis study, emphasizes a favorable safety profile, and will continue developing barzolvolimab in other indications; Phase‑3 topline data for chronic spontaneous urticaria are expected in Sep/Oct 2026. » Mere på de.investing.com

Shares of Celldex Therapeutics climbed to a new 52-week high of $39.16, having nearly doubled from a low of $19.72 and bringing market capitalization to about $3.07 billion. Investor confidence is supported by positive clinical data, including promising Phase 1 results for CDX-622 and continued improvements with barzolvolimab in angioedema. Several analysts raised their valuations or maintained buy ratings (UBS: Buy; Wells Fargo: Overweight with a $54 target; Barclays: upgraded to Overweight), while InvestingPro rates the stock as overvalued relative to its fair value. » Mere på de.investing.com

Celldex reported updated Phase 2 findings showing barzolvolimab produced rapid, sustained improvements in angioedema and chronic spontaneous urticaria symptoms, with benefits evident seven months after dosing. UBS raised its price target and kept a Buy rating, citing a favorable Phase 3 outlook that could enable approval in 2027. The data bolster barzolvolimab’s potential to move CSU treatment toward disease modification and support continued Phase 3 evaluation. » Mere på finance.yahoo.com